Newsletter 9 - Oct 2015

Dynamic Kick-Off Meeting for New COMBACTE Proposals

It seems like a long time since we first started planning the Open Call process and after many communications and discussions here we were meeting the successful companies face to face for the first time for the kick-off meeting. The gathering held in Amsterdam on the 7th of September was kept intentionally small, with the object being to showcase the capabilities of COMBACTE and to start discussions around developing the proposals.
Read more..

Phase III Collaboration with COMBACTE-CARE

On the 17th of September, AstraZeneca confirmed entering into an agreement with the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) to drive forward its antibiotic portfolio and address the growing threat of infectious diseases. Under the terms of the agreement, BARDA will initially provide $50 million toward the development of ATM-AVI. Read more..

COMBACTE Launches New Logos

Perhaps you have already noticed the slight change in this edition of the COMBACTE newsletter and on the COMBACTE website. Indeed we’ve had a bit of makeover! We are happy to share with you the new COMBACTE, COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET logos. Read more..

Introducing EURECA

EURECA, a prospective, multinational, multicentre, observational and analytic study with a matched case‐control‐control, and matched cohorts designs will be developed in coordination with CLIN‐Net, LAB‐Net and STAT‐Net. Around 50 hospitals from Spain, Italy, Greece, Turkey, Serbia, Croatia, Bosnia and Herzegovina, Albania, Macedonia, Kosovo, Bulgaria, and Romania will participate. Read more..


More news


Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!

Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

Email Marketing Powered by Mailchimp